ALX Oncology Holdings Inc. Common Stock (ALXO)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with whether there is a business earning money. ALX Oncology is a clinical-stage immuno-oncology company with 48 employees; its lead candidate, Evorpacept, is in phase 2 for gastric/GEJ cancer and has a collaboration with Jazz. But filed figures show no revenue in fiscal Q2 2026, fiscal Q1 2026, fiscal 2025, fiscal 2024, and fiscal 2023. It is a collection of cash and hopes, not a proven enterprise. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $18.0M and diluted EPS was -$0.13. Fiscal Q1 2026 net loss was $17.9M and EPS was -$0.17. Fiscal 2025 net loss was $101.7M and EPS was -$1.90; fiscal 2024 was -$134.8M and -$2.58; fiscal 2023 was -$160.8M and -$3.74. Losses are narrowing, but the company still burns cash: trailing twelve-month free cash flow was -$71.0M, a FCF yield of -52.4% of market cap. At the close on 2026-10-13, price was $0.98 and market cap was $135.5M. FairStock calculates P/E of -0.85, P/B of 1.00, ROE of -80.65%, ROCE of -40.40%, and D/E of 0.08. Low debt is a positive, but Piotroski 1/9 and Altman -2.34 suggest fragility. A durable moat is not observable; clinical data, regulatory approval, and partnerships may create value, but none is guaranteed. The stock near its 52-week low may look statistically cheap on book value, but without revenue or profits, intrinsic value is speculative.

In plain English: ALX Oncology is a small clinical-stage cancer company. It has no revenue in its recent filings and has lost money for years, so the business looks financially weak. At $0.98, the stock sits at the bottom of its 52-week range; because there are no profits to compare against, the price is hard to call cheap or expensive on business results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer